Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
FDA issued a safety communication about potential early replacement of Accolade pacemaker devices by Boston Scientific. This does not directly affect med-spa or aesthetics clinics, as it pertains to cardiac devices, not aesthetic procedures or equipment.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spa and aesthetics clinics are not affected; this is relevant to cardiology practices and patients with these pacemakers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA recommends early replacement of certain Accolade pacemakers due to potential battery failure.
Who it affects
Med-spa and aesthetics clinics are not affected; this is relevant to cardiology practices and patients with these pacemakers.
What you must do
No action required for med-spa clinics. If a clinic also provides cardiac services, they should review the FDA communication.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
- The Safer Affordable Fuel-Efficient (SAFE) Vehicles Rule for Model Years 2021-2026 Passenger Cars and Light Trucks